Drug Combination Details
| General Information of the Combination (ID: C40830) | |||||
|---|---|---|---|---|---|
| Name | Betulinic Acid NP Info | + | 4-hydroxy-tamoxifen Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | PYGO2 | Molecule Info | ||
| In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| MDA-MB-436 | CVCL_0623 | Invasive breast carcinoma | Homo sapiens | |||
| MDA-MB-468 | CVCL_0419 | Breast adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Selective estrogen receptor modulators and betulinic acid act synergistically to target ERalpha and SP1 transcription factor dependent Pygopus expression in breast cancer. | |||||
